arrow_back Back to App

Study on US Drug Manufacturing Barriers: Aiming for Lower Costs, Better Access

This act aims to investigate what hinders drug production in the United States. The goal is to understand why building new drug factories is expensive and time-consuming, and what makes the US less competitive than other countries. The study's findings are intended to help streamline regulations, potentially leading to greater drug availability and lower prices for citizens.
Key points
A study will be conducted to identify obstacles to expanding or building new drug manufacturing facilities in the US.
The study will assess whether environmental or other regulations delay and increase costs for drug production compared to other countries.
The goal is to find ways to streamline regulations to increase domestic drug manufacturing, potentially improving supply chain security and drug accessibility.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1405
Sponsor: Rep. Buchanan, Vern [R-FL-16]
Process start date: 2025-02-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Enhancing Domestic Drug Manufacturing Competitiveness Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1405.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-18.

What are the main provisions?

Key points include:

  • A study will be conducted to identify obstacles to expanding or building new drug manufacturing facilities in the US.
  • The study will assess whether environmental or other regulations delay and increase costs for drug production compared to other countries.
  • The goal is to find ways to streamline regulations to increase domestic drug manufacturing, potentially improving supply chain security and drug accessibility.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Buchanan, Vern [R-FL-16].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Economy